Results 171 to 180 of about 426,190 (338)
Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack +16 more
wiley +1 more source
A universal concept for melting in mantle upwellings. [PDF]
Schmidt MW, Paneva N, Giuliani A.
europepmc +1 more source
The Loss of a Canadian Chinook in Afghanistan: The Pilot’s Recollection of 5 August 2010 [PDF]
Craig Mantle
core +1 more source
Understanding the course and dynamics of ancient river systems, such as the pre‐Odra, provides valuable insights into the post‐glacial evolution of landscapes and riverine processes. The northwest‐trending pre‐Odra was an important drainage system of the European mainland into the Baltic Basin during and after the Scandinavian Ice Sheet retreat ...
Maryse C. Schmidt +4 more
wiley +1 more source
Upper mantle low-velocity layer tied to volatile-charged carbonate melts. [PDF]
Huang Y +6 more
europepmc +1 more source
Beneath the Mantle of Mantle Cell Lymphoma
openaire +2 more sources
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich +7 more
wiley +1 more source
Himalayan sub-Moho earthquakes suggest crustal faults trigger eclogitized-drip tectonics. [PDF]
Song X, Klemperer SL.
europepmc +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source

